NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT06161519
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06161558
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Phase 2
Recruiting
- Conditions
- Small Cell Carcinoma of the BladderSquamous Cell Carcinoma of the Urinary TractSmall Cell Carcinoma of the Urinary TractRenal Medullary CarcinomaPrimary Adenocarcinoma of the BladderPrimary Adenocarcinoma of the Urinary TractSquamous Cell Carcinoma of the BladderSquamous Cell Carcinoma of the Penis
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06161532
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Stage IV Squamous Cell Carcinoma of the Head and NeckStage II Squamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT06161545
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06149481
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
Phase 2
Active, not recruiting
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyProcedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: EchocardiographyProcedure: Echocardiography TestBiological: PertuzumabProcedure: Radiologic ExaminationBiological: Trastuzumab
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT06136897
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Phase 2
Recruiting
- Conditions
- Malignant Female Reproductive System NeoplasmMalignant Solid NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06126276
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸UC San Diego Health System - Encinitas, Encinitas, California, United States
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3
Not yet recruiting
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanRadiation: Radiation Therapy
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
18F-Fluciclovine PET/CT in Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- Drug: 18F-fluciclovine injectionProcedure: 18F-FDG PET/CT
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06103838
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal AdenocarcinomaRecurrent Colorectal AdenocarcinomaRefractory Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC v8
- Interventions
- Drug: BET Bromodomain Inhibitor ZEN-3694Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06102902
- Locations
- 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath